Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

February 3, 2015

Primary Completion Date

March 21, 2022

Study Completion Date

March 21, 2022

Conditions
Chronic Thromboembolic Pulmonary Hypertension
Interventions
DRUG

Macitentan

Macitentan 10mg, oral tablet, once daily

Trial Locations (33)

Unknown

Leuven

Beijing

Guangzhou

Shanghai

Shenyang

Wuhan

Prague

Le Kremlin-Bicêtre

Paris

Toulouse

Giessen

Heidelberg

Würzburg

Budapest

Debrecen

Kaunas

Mexico City

Lublin

Wroclaw

Kemerovo

Moscow

Novosibirsk

Saint Petersburg

Tomsk

Zurich

Bangkok

Chiang Mai

Capa_Istanbul

Kyiv

Lviv

Cambridge

London

Sheffield

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Actelion

INDUSTRY